Stocks and Investing
Stocks and Investing
Tue, July 21, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Gregory Renza Maintained (ACAD) at Buy with Decreased Target to $55 on, Jul 21st, 2020
Gregory Renza of RBC Capital, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $61 to $55 on, Jul 21st, 2020.
Gregory has made no other calls on ACAD in the last 4 months.
There are 3 other peers that have a rating on ACAD. Out of the 3 peers that are also analyzing ACAD, 0 agree with Gregory's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Gregory
- Paul Matteis of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $71 on, Tuesday, July 7th, 2020
- Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $60 on, Thursday, April 16th, 2020
- Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $72 on, Tuesday, March 31st, 2020
Contributing Sources